BOSTON (Reuters)—The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic. John Kapoor, Insys’ majority shareholder who stepped down as chief executive in January, was charged…
Rhode Island Doctor Pleads Guilty to Opioid Kickback Scheme
BOSTON (Reuters)—A Rhode Island doctor pleaded guilty on Wednesday to charges he participated in a scheme to obtain kickbacks in exchange for writing prescriptions for an addictive fentanyl-based cancer pain drug produced by Insys Therapeutics Inc. The plea by Jerrold Rosenberg came amid ongoing investigations of Insys related to Subsys, an under-the-tongue spray that contains…
U.S. Judge in Texas Invalidates Allergan Patents on Restasis
(Reuters)—A U.S. judge invalidated patents on Allergan Plc’.s dry eye medicine Restasis on the grounds that the patents cover obvious ideas, a decision that drove the pharmaceutical company’s shares down more than 6%. Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers led…
Trump Healthcare Order Could Face Strong Legal Objections
(Reuters)—U.S. President Donald Trump’s expected plan to let Americans buy insurance across state lines could violate federal law governing employee benefit plans and will almost certainly be challenged in court, several legal experts said. Trump said on Tuesday he would likely sign an executive order this week allowing people to cross state lines to obtain…
New Jersey Sues Insys as Opioid Maker Settles with Massachusetts
BOSTON (Reuters)—New Jersey on Thursday accused Insys Therapeutics Inc of engaging in a fraudulent scheme to boost sales of a fentanyl-based cancer pain drug, as Massachusetts announced a $500,000 settlement with the drugmaker to resolve similar allegations. The lawsuit by New Jersey Attorney General Christopher Porrino accused Insys of illegally directing its sales force to…
U.S. House Committee Launches Probe of Allergan Patent Deal
NEW YORK (Reuters)—A U.S. House of Representatives committee launched a probe into drugmaker Allergan Plc’s deal to transfer some of its patents to a Native American tribe to shield them from review. A bipartisan group of four representatives from the House Oversight and Government Committee, including Republican Chairman Trey Gowdy and top Democrat Elijah Cummings,…
Washington State Sues OxyContin Maker Purdue Pharma
(Reuters)—Washington state on Thursday sued OxyContin maker Purdue Pharma LP, becoming the latest state or local government to file a lawsuit seeking to hold pharmaceutical companies accountable for a national opioid addiction epidemic. The city of Seattle also filed a separate lawsuit against Purdue as well as units of Teva Pharmaceutical Industries Ltd, Johnson and…
Pfizer Files Suit Against J and J over Remicade Contracts
(Reuters)—Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson and Johnson, saying its rival’s contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer’s new biosimilar. Pfizer said in the suit that Johnson and Johnson is offering discounts on its Remicade treatment in exchange for essentially excluding…
Prosecutors Identify Insys Founder as Unindicted Co-conspirator in Opioid Case
BOSTON (Reuters)—U.S. prosecutors have identified Insys Therapeutics Inc’s billionaire founder as an unindicted co-conspirator in a case accusing six former executives and managers of participating in a scheme that involved bribing doctors to prescribe a fentanyl-based drug, according to a court document. John Kapoor, who stepped down as chief executive of Insys in January, was…
U.S. Tribal Patent Deal Could Impact Generic Drug Market
(Reuters)—A groundbreaking deal between Allergan Plc. and a Native American tribe to shield the company’s patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts say, potentially dealing a blow to generic competition. Allergan said on Friday it had transferred patents on its blockbuster dry eye…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 18
- Next Page »